Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc. [The Motley Fool]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: The Motley Fool
Positive results for similar candidates recently boosted both of these biotech stocks, but which is the better pick right now? If you're like most people, you've never heard of non-alcoholic steatohepatitis (NASH), even though the epidemic threatens the lives of perhaps 20 million Americans right now. There aren't any available treatments that stop immune systems from damaging fatty livers, but Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) and Viking Therapeutics, Inc. ( NASDAQ:VKTX ) are both developing potential new NASH drugs, and investors are wondering which is the better stock to pick right now. Madrigal and Viking recently provided some updates to clinical trial programs that could make a difference for millions of NASH patients in need of a treatment option. Let's stack them side by side to see which one comes out on top. Image source: Getty Images. The results so far Earlier this year, Viking Therapeutics stock rocketed higher when the com
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- 2 Under-the-Radar Growth Stocks to Consider [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisGlobeNewswire